{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.891304"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"46"}],"units":"Participants"}],"description":"Proportion of participants having GATA1 mutation among patients with phenotype data available.","groups":[{"description":"INDUCTION THERAPY COURSE I: Patients receive cytarabine IT on day 1 and cytarabine IV continuously over 96 hours, daunorubicin hydrochloride IV continuously, and oral thioguanine BID on days 1-4.\n\nCOURSE II: Patients receive high-dose cytarabine IV over 3 hours BID on days 1, 2, 8, and 9 and asparaginase (IM) on days 2 and 9.\n\nCOURSE III: Patients receive treatment as in course I. COURSE IV: Patients receive cytarabine IV, daunorubicin hydrochloride IV, and oral thioguanine as in course I INTENSIFICATION THERAPY: Patients receive cytarabine IV continuously over 168 hours on days 1-7 and etoposide IV over 1 hour on days 1-3. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.\n\nasparaginase: Given IM daunorubicin hydrochloride: Given IV cytarabine: Given IV or IT thioguanine: Given orally etoposide: Given IV laboratory biomarker analysis: Correlative studies","id":"OG000","title":"Treatment (Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Ineligible patients (n=1) are excluded. Patients without available or evaluable phenotype data are excluded (n=158). Data are not available at end of therapy or relapse.","reportingStatus":"POSTED","timeFrame":"At baseline and at the end of therapy (intensification) or disease relapse","title":"Prevalence of of GATA1 Mutations of DS Patients < 4 Years of Age at Diagnosis","type":"SECONDARY","unitOfMeasure":"Proportion of participants"}